GlassScriptPhysician profile
Todd K Holtz
NPI 1982695375
$4,505.23
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $816 · 2020: $317 · 2021: $647 · 2022: $1,222 · 2023: $1,140 · 2024: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,475 · Education: $27.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,474.99 |
| Education | $27.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,048.72 | 2019-2024 | |
| Pfizer INC. | $554.35 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $403.58 | 2019-2023 | Xifaxan |
| Janssen Biotech, INC. | $401.27 | 2019-2023 | Stelara |
| Gilead Sciences, INC. | $378.68 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $311.15 | 2019-2023 | Entyvio |
| Celgene Corporation | $191.51 | 2021-2023 | Zeposia |
| Ferring Pharmaceuticals INC. | $129.42 | 2021-2023 | Rebyota |
| Braintree Laboratories, INC. | $124.31 | 2021-2023 | Sutab |
| Intercept Pharmaceuticals, INC. | $119.12 | 2019-2023 | Ocaliva |
| Qol Medical, LLC | $114.11 | 2024 | Sucraid |
| Genzyme Corporation | $106.97 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $103.51 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $102.76 | 2021-2023 | Linzess |
| Ucb, INC. | $97.22 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $40.75 | 2023 | Ibsrela |
| Daiichi Sankyo INC. | $40.11 | 2019-2022 | |
| Shionogi INC | $33.22 | 2019 | |
| Amgen INC. | $30.31 | 2023 | Amjevita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.25 | 2023 | Cyltezo |
| Madrigal Pharmaceuticals | $28.20 | 2024 | Resmetirom |
| Celltrion USA INC. | $27.43 | 2023 | Yuflyma |
| Shire North American Group INC | $19.63 | 2019 | |
| Aimmune Therapeutics, INC. | $19.63 | 2023 | |
| Organon LLC | $19.10 | 2023 | Hadlima |
| Nestle Healthcare Nutrition INC. | $18.05 | 2023 | |
| Boston Scientific Corporation | $13.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Holtz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.